Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Accumulated Depreciation & Amortization (2016 - 2022)

Akebia Therapeutics (AKBA) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $1.7 million as the latest value for Q4 2022.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 14.17% to $1.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $1.7 million, a 14.17% decrease, with the full-year FY2022 number at $1.7 million, down 14.17% from a year prior.
  • Accumulated Depreciation & Amortization was $1.7 million for Q4 2022 at Akebia Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $5.2 million in Q3 2020 to a low of $899000.0 in Q4 2018.
  • A 5-year average of $2.5 million and a median of $2.1 million in 2020 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: dropped 15.11% in 2018, then soared 149.72% in 2019.
  • Akebia Therapeutics' Accumulated Depreciation & Amortization stood at $899000.0 in 2018, then skyrocketed by 149.72% to $2.2 million in 2019, then dropped by 7.57% to $2.1 million in 2020, then dropped by 7.13% to $1.9 million in 2021, then dropped by 14.17% to $1.7 million in 2022.
  • Per Business Quant, the three most recent readings for AKBA's Accumulated Depreciation & Amortization are $1.7 million (Q4 2022), $1.9 million (Q4 2021), and $2.1 million (Q4 2020).